Issue 3/2009
Content (14 Articles)
N-benzoxazol-2-yl-N′-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potential
Johann Hofmann, Johnny Easmon, Gerhard Puerstinger, Gottfried Heinisch, Marcel Jenny, Alexander A. Shtil, Martin Hermann, Daniele F. Condorelli, Salvatore Sciré, Giuseppe Musumarra
Hesperetin exerts dose dependent chemopreventive effect against 1,2-dimethyl hydrazine induced rat colon carcinogenesis
Selvaraj Aranganathan, Jayabal Panneer Selvam, Namasivayam Nalini
Antioxidant and anticancer efficacy of hesperidin in benzo(a)pyrene induced lung carcinogenesis in mice
Sattu Kamaraj, Gopalakrishnan Ramakrishnan, Pandi Anandakumar, Sundaram Jagan, Thiruvengadam Devaki
Antitumor activity of a novel series of α-aryloxy-α-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines
Xishan Xiong, Yangliang Ye, Lili Fu, Bing Dai, Jieqiong Liu, Jieshuang Jia, Jing Tang, Lin Li, Li Wang, Jianhua Shen, Changlin Mei
Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis
Gopalakrishnan Ramakrishnan, Sundaram Jagan, Sattu Kamaraj, Pandi Anandakumar, Thiruvengadam Devaki
Antiviral activity of cidofovir against telomerase-specific replication-selective oncolytic adenovirus, OBP-301 (Telomelysin)
Masaaki Ouchi, Hitoshi Kawamura, Yasuo Urata, Toshiyoshi Fujiwara
Nimbolide a limonoid from Azadirachta indica inhibits proliferation and induces apoptosis of human choriocarcinoma (BeWo) cells
G. Harish Kumar, K.V.P. Chandra Mohan, A. Jagannadha Rao, S. Nagini
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Michael Michael, Peter Gibbs, Robert Smith, Alex Godwood, Stuart Oliver, Niall Tebbutt
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients
Lisardo Ugidos, Salvadora Delgado, Carlos Conill, Angels Ginés, Rosa Gallego, Juan Ramón Ayuso, Rosa Miquel, Monica Tosca, Antonio de Lacy, Antoni Castells, Joan Maurel
A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
Sun Young Kim, Yong Sang Hong, Byung Chang Kim, Ji Won Park, Hyo Seong Choi, Seung-Yong Jeong, Dae Yong Kim, Chang Won Hong, Dae Kyung Sohn, Kyung Hae Jung
A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer
Bryan H. Burmeister, Euan T. Walpole, Nancy D’Arcy, Elizabeth A. Burmeister, Sharon Cox, Damien B. Thomson, Jennifer A. Harvey, B. Mark Smithers
Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs
L.-C. Steve Wang, Lai-Ming Ching, James W. Paxton, Philip Kestell, Rachel Sutherland, Li Zhuang, Bruce C. Baguley
Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
V. Prulière-Escabasse, E. Escudier, R. Balheda, J. C. Soria, A. Coste, C. Massard
Publication biases and phase II trials investigating anticancer targeted therapies
Nicolas Penel, Antoine Adenis